A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor

NCT04444895 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

73

Enrollment

INDUSTRY

Sponsor class

Conditions

Angioedema

Interventions

DRUG: Lanadelumab

Sponsor

Shire

Collaborators

[object Object]